Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-742-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.73 million
Profitability
Miscellaneous
Employees170
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics Inc (NASDAQ:RVNC) released its quarterly earnings data on Monday, August, 5th. The biopharmaceutical company reported ($0.86) EPS for the quarter, hitting the consensus estimate of ($0.86). Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 79.28%. View Revance Therapeutics' Earnings History.
When is Revance Therapeutics' next earnings date?
What price target have analysts set for RVNC?
9 brokers have issued twelve-month price targets for Revance Therapeutics' stock. Their predictions range from $17.83 to $50.00. On average, they anticipate Revance Therapeutics' share price to reach $34.35 in the next year. This suggests a possible upside of 145.0% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.
What is the consensus analysts' recommendation for Revance Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.
What are Wall Street analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (10/9/2019)
- 2. Mizuho analysts commented, "We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT." (4/24/2019)
- 3. HC Wainwright analysts commented, "Our $25 price target for Revance is based on our sum of the parts NPV valuation based on each of RT-002’s targeted indications. Our DCF model utilizes a WACC-derived discount rate of 12.2% (Beta of 1.4, equity risk premium of 6.7%). We adjust each indication for probability of success with glabellar lines at 85%, cervical dystonia at 80%, plantar fasciitis at 25%, chronic migraine at 35% and upper limb spasticity at 80%." (2/14/2019)
Has Revance Therapeutics been receiving favorable news coverage?
Press coverage about RVNC stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Revance Therapeutics earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Revance Therapeutics.
Are investors shorting Revance Therapeutics?
Revance Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,310,000 shares, an increase of 6.2% from the August 30th total of 5,000,000 shares. Based on an average trading volume of 356,600 shares, the days-to-cover ratio is currently 14.9 days. Approximately 13.9% of the company's shares are short sold. View Revance Therapeutics' Current Options Chain.
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include Cambrex (CBM), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Intercept Pharmaceuticals (ICPT), Zai Lab (ZLAB), Xencor (XNCR), Agios Pharmaceuticals (AGIO), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Zogenix (ZGNX), Prestige Consumer Healthcare (PBH), Deciphera Pharmaceuticals (DCPH), Apellis Pharmaceuticals (APLS), Uniqure (QURE) and Corcept Therapeutics (CORT).
What other stocks do shareholders of Revance Therapeutics own?
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
- Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
- Dr. Abhay Joshi, Chief Operating Officer (Age 56)
- Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
- Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications
How do I buy shares of Revance Therapeutics?
Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
One share of RVNC stock can currently be purchased for approximately $14.02.
How big of a company is Revance Therapeutics?
Revance Therapeutics has a market capitalization of $618.28 million and generates $3.73 million in revenue each year. The biopharmaceutical company earns $-142,570,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.View Additional Information About Revance Therapeutics.
What is Revance Therapeutics' official website?
How can I contact Revance Therapeutics?
Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]
MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
